Stock data
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA) reported net income of -US$13.56M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$13.99M | -US$13.56M | — |
| 2024 | — | — | -US$12.05M | -US$11.85M | — |
| 2023 | — | — | -US$11.46M | -US$11.12M | — |
| 2022 | US$0.00M | — | -US$27.53M | -US$27.42M | — |
| 2021 | US$0.00M | — | -US$12.13M | -US$11.43M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$3.27M | — |
| 2026-03-31 | — | -US$3.38M | — |
| 2025-12-31 | — | -US$3.36M | — |
| 2025-09-30 | — | -US$3.44M | — |
| 2025-06-30 | — | -US$3.93M | — |
| 2025-03-31 | — | -US$2.83M | — |
| 2024-12-31 | — | -US$2.73M | — |
| 2024-09-30 | — | -US$3.38M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.